On June 24, 2021, The Society for Post-Acute and Long-Term Care Medicine posted a statement regarding the approval of dementia medication aducanumab. Below is a segment of their statement: “The Society for Post-Acute and Long-Term Care Medicine is compelled to comment on the recent approval of the controversial parenteral Alzheimer’s Dementia (AD) medication, aducanumab. After considering the evidence, we conclude …
“The National Center for Health Statistics reports that 16.5% of long-term care residents are younger than 65 (Vital Health State 3 2016;38:x-xii, 1-105). However, we know that some LTC facilities tend to have higher concentrations of younger adults, and it is not uncommon to encounter individuals in their 20s. Younger adults who reside in LTC settings often fall into one …
To help members who are having trouble getting ahold of personal protective equipment, The Society for Post-Acute and Long-Term Care Medicine (AMDA) is working with Project N95 to purchase and offer such items at bulk pricing rates. There are no minimum order quantities, but the offer is only for a one-time bulk purchase and may not be repeated. The following …
Long-term care clinicians have asked the federal government to delay allocating monoclonal antibody therapy to nursing homes until further study and to collaborate with facility medical directors when they do. With approval predicted in the coming weeks, the question of who should receive this treatment and how it will be provided is an open question, said AMDA – The Society …
AMDA FORMALLY ENDORSES A NATIONAL POLST FORM Press Release July 2, 2020 Columbia, MD, and Washington, DC – AMDA – The Society for Post-Acute and Long-Term Care Medicine and National POLST are excited to announce that AMDA is the first national organization to formally endorse and support the adoption of a national POLST form. The AMDA board passed the resolution …
